Augtyro is an oral treatment for ROS1-positive non-small cell lung cancer and NTRK fusion–positive tumors. It blocks key cancer-driving proteins to help slow tumor growth, especially in patients who’ve tried other therapies.
Augtyro is an oral treatment for ROS1-positive non-small cell lung cancer and NTRK fusion–positive tumors. It blocks key cancer-driving proteins to help slow tumor growth, especially in patients who’ve tried other therapies.
Molecule Name :
Innovator :
Approval Date :
NCE-1 Date :
NCE Date :
Dosage Form :
Strength :
Therapeutic Category :
Revenue ($M) :
2025 :
2026 :
2027 :
2028 :
2029 :
2030 :
2031 :




